FDA approves drug to treat neurologic manifestations of Hunter syndrome
The U.S. Food and Drug Administration approved Avlayah to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
Publication Details
- Journal
- The Brown University Child & Adolescent Psychopharmacology Update
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1002/cpu.31062
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00